ReviewCurrent opinion in hematology2011
Treatment of chronic graft-versus-host disease in 2011.
Review in Current opinion in hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Long-term follow-up of informal caregivers after allo-SCT: a systematic review.Bone marrow transplantation · 2013Pooled it
- A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Positive Effects of Oral Antibiotic Administration in Murine Chronic Graft-Versus-Host Disease.International journal of molecular sciences · 2021Article
- Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?Bone marrow transplantation · 2020Review
- Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Article
- Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Blood · 2017Review
- Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.Frontiers in immunology · 2017Article
- Article
- Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.International journal of hematology · 2015Review
- Article
- How we treat chronic graft-versus-host disease.Blood · 2015Review
- Article
- Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease.Case reports in hematology · 2015Article
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.The Journal of clinical investigation · 2014Article
- Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells.Journal of cellular and molecular medicine · 2014Article
- Extracorporeal photopheresis in the management of graft-versus-host disease.Current oncology (Toronto, Ont.) · 2014Article
- Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD.Bone marrow transplantation · 2013Article
- Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.Blood · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis article summarizes recent reports on the risks, pathogenesis and treatment of chronic graft-versus-host disease (GVHD). RECENT
findingsChronic GVHD remains an elusive disorder to characterize and to treat. Recent evidence on tolerance induction by regulatory T-cells and on B-cell involvement shed some insights into the pathogenesis of chronic GVHD. In a recent large comparative study, the overall risk profiles for acute and for chronic GVHD were similar, but risk factors were not changed after adjustment for prior acute GVHD, supporting the concept that chronic GVHD is not an end stage of acute GVHD. Glucocorticoids remain the standard initial treatment of chronic GVHD, but the outcomes are not satisfactory, particularly for patients with high-risk features. Many treatments for chronic GVHD including extracorporeal photopheresis, rituximab, sirolimus, mycofenolate mofetil, imatinib, pentostatin and infusion of mesenchymal stem cells have been reported in several retrospective and relatively small phase I/II studies with a wide range of overall responses. SUMMARY: No current therapies used for chronic GVHD have been approved by the US Food and Drug Administration. Large well designed prospective studies are warranted to establish better treatments. Targeted therapies based on the pathogenesis of chronic GVHD may lead to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.